Renal cell carcinoma: Diagnosis, staging, and surveillance

American Journal of Roentgenology

Volumn 191, Issue 4, 2008, Pages 1220-1232

  Ng, Chaan S ^f   Wood, Christopher G ^a,b,c,d,e,f   Silverman, Paul M ^f   Tannir, Nizar M ^f   Tamboli, Pheroze ^f   Sandler, Carl M ^f  

^a PFIZER INC   (United States)

^b Antigenics Inc   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d ETHICON INC   (United States)

^e Bayer Healthcare ^*

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Imaging; Renal cell carcinoma; Staging

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 2; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ABDOMINAL SCINTISCANNING; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; COURSE EVALUATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISTANT METASTASIS; EVALUATION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENE INACTIVATION; HISTOPATHOLOGY; HUMAN; KIDNEY ANGIOGRAPHY; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPH NODE METASTASIS; MEDIASTINUM METASTASIS; NEPHRECTOMY; NEPHRON SPARING SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; PATIENT MONITORING; PERCUTANEOUS BIOPSY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY; TISSUE SECTION; UPREGULATION;

CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; POPULATION SURVEILLANCE; SURVIVAL ANALYSIS;

EID: 53249111692     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.3568     Document Type: Review

References (96)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66
2. Choyke Pl, Newhouse JH, Bluth EI, et al. ACR appropriateness criteria: renal cell carcinoma staging, 2002. American College of Radiology Website. www.acr.org. Accessed December 9, 2002
3. Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma: age and stage characterization and clinical implications - study of 1092 patients (1982-1997). Urology 2000; 56:58-62
4. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 1998; 51:203-205
5. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281:1628-1631
6. Katner HP, Baynham SA. Increasing incidence of renal cell cancer. JAMA 1999; 282:2119-2120; discussion 2121
7. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166:1611-1623
8. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841
9. Choyke PL, Amis ES Jr, Bigongiari LR, et al. Renal cell carcinoma staging. American College of Radiology. ACR appropriateness criteria. Radiology 2000; 215[suppl]:721-725
10. Russo P. Renal cell carcinoma: presentation, staging, and surgical treatment. Semin Oncol 2000; 27:160-176
11. Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma: clinical, pathological, and genetic features. Am J Pathol 1996; 149:1201-1208
12. Levine E, Weigel JW, Collins DL. Diagnosis and management of asymptomatic renal cell carcinomas in von Hippel-Lindau syndrome. Urology 1983; 21:146-150
13. Figlin RA. Renal cell carcinoma: management of advanced disease. J Urol 1999; 161:381-386; discussion 386-387
14. Pretorius ES, Wickstrom ML, Siegelman ES. MR imaging of renal neoplasms. Magn Reson Imaging Clin N Am 2000; 8:813-836
15. Godley P, Kim SW. Renal cell carcinoma. Curr Opin Oncol 2002; 14:280-285
16. American Cancer Society. How is kidney cancer staged? 2007. American Cancer Society Website. www.cancer.org/docroot/CRI/content/ CRI_2_4_3X_How_is_kidney_cancer_staged_22.asp?rnav=cri. Accessed October 16, 2007
17. Hilton S. Imaging of renal cell carcinoma. Semin Oncol 2000; 27:150-159
18. Parienty RA, Pradel J, Parienty I. Cystic renal cancers: CT characteristics. Radiology 1985; 157:741-744
19. Brinker DA, Amin MB, de Peralta-Venturina M, Reuter V, Chan DY, Epstein JI. Extensively necrotic cystic renal cell carcinoma: a clinicopathologic study with comparison to other cystic and necrotic renal cancers. Am J Surg Pathol 2000; 24:988-995
20. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183:131-133
21. Shanks JH. Pathology of renal cell carcinoma: recent developments. Clin Oncol (R Coll Radiol) 1999; 11:263-268
22. Bostwick DG, Eble JN. Diagnosis and classification of renal cell carcinoma. Urol Clin North Am 1999; 26:627-635
23. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-663
24. American Joint Committee on Cancer. AJCC cancer staging manual. New York, NY: Springer-Verlag, 2002
25. Robson CJ. Staging of renal cell carcinoma. Prog Clin Biol Res 1982; 100:439-445
26. Rini BI, Vogelzang NJ. Prognostic factors in renal carcinoma. Semin Oncol 2000; 27:213-220
27. Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol 1995; 154:964-967
28. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004; 11:71-77
29. Delahunt B. Histopathologic prognostic indicators for renal cell carcinoma. Semin Diagn Pathol 1998; 15:68-76
30. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090-1095; quiz 1295
31. Staudenherz A, Steiner B, Puig S, Kainberger F, Leitha T. Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 1999; 85:153-155
32. Zagoria RJ, Bechtold RE. The role of imaging in staging renal adenocarcinoma. Semin Ultrasound CT MR 1997; 18:91-99
33. Ng CS, Loyer EM, Iyer RB, David CL, DuBrow RA, Charnsangavej C. Metastases to the pancreas from renal cell carcinoma: findings on three-phase contrast-enhanced helical CT. AJR 1999; 172:1555-1559
34. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 2007; 188:586-592
35. Choyke Pl, Amis ES, Bigongiari LR, et al. ACR appropriateness criteria: renal cell carcinoma staging, 1998. American College of Radiology Website: www.acr.org. Accessed December 9, 2002
36. Chin AI, Lam JS, Figlin RA, Belldegrun AS. Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol 2006; 8: 1-7
37. Curry NS, Francis IR, Baumgarten DA, et al. ACR appropriateness criteria: renal cell carcinoma staging, 2007. American College of Radiology Website: www.acr.org. Accessed March 27, 2008
38. Fielding JR, Aliabadi N, Renshaw AA, Silverman SG. Staging of 119 patients with renal cell carcinoma: the yield and cost-effectiveness of pelvic CT. AJR 1999; 172:23-25
39. Sheth S, Scatarige JC, Horton KM, Corl FM, Fishman EK. Current concepts in the diagnosis and management of renal cell carcinoma: role of multidetector CT and three-dimensional CT. RadioGraphics 2001; 21[spec no]:S237-S254
40. Urban BA, Ratner LE, Fishman EK. Three-dimensional volume-rendered CT angiography of the renal arteries and veins: normal anatomy, variants, and clinical applications. RadioGraphics 2001; 21:373-386; questionnaire 549-555
41. Wunderlich H, Reichelt O, Schubert R, Zermann DH, Schubert J. Preoperative simulation of partial nephrectomy with three-dimensional computed tomography. BJU Int 2000; 86:777-781
42. Kopka L, Fischer U, Zoeller G, Schmidt C, Ringert RH, Grabbe E. Dual-phase helical CT of the kidney: value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma. AJR 1997; 169:1573-1578
43. Yuh BI, Cohan RH. Different phases of renal enhancement: role in detecting and characterizing renal masses during helical CT. AJR 1999; 173: 747-755
44. Kim JK, Kim TK, Ahn HJ, Kim CS, Kim KR, Cho KS. Differentiation of subtypes of renal cell carcinoma on helical CT scans. AJR 2002; 178: 1499-1506
45. Herts BR, Coll DM, Novick AC, et al. Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys. AJR 2002; 178:367-372
46. Beer AJ, Dobritz M, Zantl N, Weirich G, Stollfuss J, Rummeny EJ. Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR 2006; 186:1639-1650
47. Choyke PL. Detection and staging of renal cancer. Magn Reson Imaging Clin N Am 1997; 5:29-47
48. Zhang J, Israel GM, Krinsky GA, Lee VS. Masses and pseudomasses of the kidney: imaging spectrum on MR. J Comput Assist Tomogr 2004; 28:588-595
49. Hallscheidt PJ, Fink C, Haferkamp A, et al. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr 2005; 29:64-68
50. Tuite DJ, Geoghegan T, McCauley G, Govender P, Browne RJ, Torreggiani WC. Three-dimensional gadolinium-enhanced magnetic resonance breath-hold FLASH imaging in the diagnosis and staging of renal cell carcinoma. Clin Radiol 2006; 61: 23-30
51. Hallscheidt PJ, Bock M, Riedasch G, et al. Diagnostic accuracy of staging renal cell carcinomas using multidetector-row computed tomography and magnetic resonance imaging: a prospective study with histopathologic correlation. J Comput Assist Tomogr 2004; 28:333-339
52. Frohmuller HG, Grups JW, Heller V. Comparative value of ultrasonography, computerized tomography, angiography and excretory urography in the staging of renal cell carcinoma. J Urol 1987; 138:482-484
53. Bos SD, Mensink HJ. Can duplex Doppler ultrasound replace computerized tomography in staging patients with renal cell carcinoma? Scand J Urol Nephrol 1998; 32:87-91
54. Habboub HK, Abu-Yousef MM, Williams RD, See WA, Schweiger GD. Accuracy of color Doppler sonography in assessing venous thrombus extension in renal cell carcinoma. AJR 1997; 168: 267-271
55. Fritzsche PJ, Millar C. Multimodality approach to staging renal cell carcinoma. Urol Radiol 1992; 14:3-7
56. Campbell SC, Fichtner J, Novick AC, et al. Intraoperative evaluation of renal cell carcinoma: a prospective study of the role of ultrasonography and histopathological frozen sections. J Urol 1996; 155:1191-1195
57. Novick AC. Advances in the management of local ized renal cell cancer. Can J Urol 2000; 7:960-966
58. Montravers F, Grahek D, Kerrou K, et al. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera. J Nucl Med 2000; 41:78-84
59. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825-830
60. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control 2002; 9:335-342
61. Majhail NS, Urbain JL, Albani JM, et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 2003; 21:3995-4000
62. Marshall FF, Stewart AK, Menck HR. The National Cancer Data Base: report on kidney cancers. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1997; 80:2167-2174
63. Catalano C, Fraioli F, Laghi A, et al. High-resolution multidetector CT in the preoperative evaluation of patients with renal cell carcinoma. AJR 2003; 180:1271-1277
64. Sandock DS, Seftel AD, Resnick MI. Adrenal metastases from renal cell carcinoma: role of ipsilateral adrenalectomy and definition of stage. Urology 1997; 49:28-31
65. Hafron J, Kaouk JH. Ablative techniques for the management of kidney cancer. Nat Clin Pract Urol 2007; 4:261-269
66. Giberti C, Oneto F, Martorana G, Rovida S, Carmignani G. Radical nephrectomy for renal cell carcinoma: long-term results and prognostic factors on a series of 328 cases. Eur Urol 1997; 31: 40-48
67. Blom JH, van Poppel H, Marechal JM, et al.; EORTC Genitourinary Group. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. Eur Urol 1999; 36:570-575
68. Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR 1987; 148:59-63
69. Fein AB, Lee JK, Balfe DM, et al. Diagnosis and staging of renal cell carcinoma: a comparison of MR imaging and CT. AJR 1987; 148:749-753
70. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144:243-245
71. Saidi JA, Newhouse JH, Sawczuk IS. Radiologic follow-up of patients with T1-3a,b,c or T4N+M0 renal cell carcinoma after radical nephrectomy. Urology 1998; 52:1000-1003
72. Johnsen JA, Hellsten S. Lymphatogenous spread of renal cell carcinoma: an autopsy study. J Urol 1997; 157:450-453
73. Schafhauser W, Ebert A, Brod J, Petsch S, Schrott KM. Lymph node involvement in renal cell carcinoma and survival chance by systematic lymphadenectomy. Anticancer Res 1999; 19:1573-1578
74. Kearney GP, Waters WB, Klein LA, Richie JP, Gittes RF. Results of inferior vena cava resection for renal cell carcinoma. J Urol 1981; 125:769- 773
75. Davits RJ, Blom JH, Schroder FH. Surgical management of renal carcinoma with extensive involvement of the vena cava and right atrium. Br J Urol 1992; 70:591-593
76. Kallman DA, King BF, Hattery RR, et al. Renal vein and inferior vena cava tumor thrombus in renal cell carcinoma: CT, US, MRI and venacavography. J Comput Assist Tomogr 1992; 16:240-247
77. Oto A, Herts BR, Remer EM, Novick AC. Inferior vena cava tumor thrombus in renal cell carcinoma: staging by MR imaging and impact on surgical treatment. AJR 1998; 171:1619-1624
78. Welch TJ, LeRoy AJ. Helical and electron beam CT scanning in the evaluation of renal vein involvement in patients with renal cell carcinoma. J Comput Assist Tomogr 1997; 21:467-471
79. Hricak H, Thoeni RF, Carroll PR, Demas BE, Marotti M, Tanagho EA. Detection and staging of renal neoplasms: a reassessment of MR imaging. Radiology 1988; 166:643-649
80. Roubidoux MA, Dunnick NR, Sostman HD, Leder RA. Renal carcinoma: detection of venous extension with gradient-echo MR imaging. Radiology 1992; 182:269-272
81. Goldfarb DA, Novick AC, Lorig R, et al. Magnetic resonance imaging for assessment of vena caval tumor thrombi: a comparative study with venacavography and computerized tomography scanning. J Urol 1990; 144:1100-1103; discussion 1103-1104
82. Hatcher PA, Anderson EE, Paulson DF, Carson CC, Robertson JE. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991;145:20-23; discussion 23-24
83. Kassouf W, Sanchez-Ortiz R, Tamboli P, et al. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M. D. Anderson Cancer Center experience. Urology 2007; 69:835-838
84. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-3132
85. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141
86. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon-alfa in metastatic renalcell carcinoma. N Engl J Med 2007; 356:115-124
87. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007; 25[meeting abstracts suppl]:5024
88. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134
89. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon-alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281
90. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 2007; 25[meeting abstracts suppl]:5033
91. Escudier B, Koralewski P, Pluzanska A, et al. A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-{alpha}2a vs placebo/interferon-{alpha}2a as first-line therapy in metastatic renal cell carcinoma. J Clin Oncol 2007; 25[meeting abstracts suppl]:3
92. Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164:322-325
93. Chae EJ, Kim JK, Kim SH, Bae SJ, Cho KS. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 2005; 234:189-196
94. Sella A, Swanson DA, Ro JY, et al. Surgery following response to interferon-alpha-based therapy for residual renal cell carcinoma. J Urol 1993; 149:19-21; discussion 21-22
95. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage-specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163-1167
96. Baltaci S, Orhan D, Soyupek S, Beduk Y, Tulunay O, Gogus O. Influence of tumor stage, size, grade, vascular involvement, histological cell type and histological pattern on multifocality of renal cell carcinoma. J Urol 2000; 164:36-39